Study of a Pandemic Influenza Vaccine in Elderly Participants

Seqirus200 enrolled

Overview

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic. The elderly are likely to be a special target group for vaccination; therefore, this study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in a healthy elderly population.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

200

Conditions

Influenza

Interventions

H5N1 Pandemic Influenza VaccineBIOLOGICAL

Eligibility

Sex: ALLMin age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy male and female participants Exclusion Criteria: * History of clinically significant medical conditions * History of Guillain-Barre syndrome or active neurological disease * Resident of nursing home or long-term care facility

Locations (2)

CMAX, a division of IDT Australia

Adelaide, South Australia, Australia

Princess Margaret Hospital for Children

Perth, Western Australia, Australia

Outcomes

Primary Outcomes

Safety and immunogenicity

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.